Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis

Keng-Liang Wu; Eng-Yen Huang; Wen-Ling Yeh; Chang-Chun Hsiao; Chung-Mou Kuo

doi:10.18632/oncotarget.18721

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis

Keng-Liang Wu, Eng-Yen Huang, Wen-Ling Yeh, Chang-Chun Hsiao _ and Chung-Mou Kuo

PDF | HTML | How to cite

Oncotarget. 2017; 8:61935-61943. https://doi.org/10.18632/oncotarget.18721

Metrics: PDF 2069 views | HTML 3297 views | ?

Abstract

Keng-Liang Wu1,2,3, Eng-Yen Huang4,5, Wen-Ling Yeh1, Chang-Chun Hsiao2,6 and Chung-Mou Kuo1,3

1Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

2Graduate Institute of Clinical Medical Sciences, Chang Gung University, Kaohsiung, Taiwan

3Chang Gung University, College of Medicine, Kaohsiung, Taiwan

4Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

5School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Kaohsiung, Taiwan

6Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Correspondence to:

Chang-Chun Hsiao, email: [email protected]

Keywords: colorectal cancer, galectin-3, carcinoembryonic antigen, cancer cell migration

Received: February 09, 2017 Accepted: May 22, 2017 Published: June 27, 2017

ABSTRACT

In this study, we investigated the role of galectin-3 and carcinoembryonic antigen (CEA) in metastasis and survival of colorectal cancer (CRC) patients. CEA interacted with galectin-3 at the cell surface and cytoplasm of Caco2 and DLD1 CRC cells. Knocking down galectin-3 did not affect CEA expression in CRC cells. However, there was a dose-dependent increase in CRC cell migration upon addition of small amounts of exogenous CEA (≤1ng/ml). Galectin-3 knockdown blocked induction of CRC cell migration by CEA, suggesting interaction between galectin-3 and CEA was necessary for CRC cell migration. Exogenous CEA and galectin-3 synergistically promoted migration of galectin-3 knockdown DLD1 cells. Immunohistochemical analysis showed that CEA co-localized with galectin-3 in CRC patient tissues. In additon, advanced stage CRC patients had higher serum galectin-3 and CEA levels than early stage CRC patients. High serum CEA and galectin-3 levels correlated with advanced N stage and poor survival in CRC patients. These findings suggest interaction between galectin-3 and CEA promotes CRC migration and metastasis, and correlates with poor survival of CRC patients. Thus combinatorial therapy targeting galectin-3 and CEA may improve outcomes for advanced stage CRC patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18721

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis

Abstract